基于生物信息学分析TRIB2与结肠癌预后和免疫浸润相关性

doi:10.20223/j.cnki.1000-8535.2025.06.006

广州医药 ›› 2025, Vol. 56 ›› Issue (6): 766-774.DOI: 10.20223/j.cnki.1000-8535.2025.06.006

基于生物信息学分析TRIB2与结肠癌预后和免疫浸润相关性

万璐颖^{1, 2}, 李静宜¹, 谢贤和^{1, 2, 3}

1 福建医科大学附属第一医院肿瘤内科（福建福州 350005）;
2 福建医科大学附属第一医院滨海院区国家区域医疗中心肿瘤内科（福建福州 350212）;
3 福建医科大学附属第一医院肿瘤精准医学福建省重点实验室（福建福州 350005）

收稿日期:2024-04-30 发布日期:2025-07-23
通讯作者: 谢贤和,E-mail：xiexianhe@fjmu.edu.cn
基金资助:
福建省教育厅中青年教师教育科研项目（JAT210092）

Correlation of TRIB2 expression with prognosis and immune infiltration in colon cancer based on bioinformatics

WAN Luying^1,2, LI Jingyi¹, XIE Xianhe^1,2,3

1 Department of Oncology,Molecular Oncology Research Institute,The First Affiliated Hospital,Fujian Medical University,Fuzhou 350005,China;
2 Department of Oncology,National Regional Medical Center,Binhai Campus of The First Affiliated Hospital,Fujian Medical University,Fuzhou 350212,China;
3 Fujian Key Laboratory of Precision Medicine for Cancer,The First Affiliated Hospital,Fujian Medical University,Fuzhou 350005,China

Received:2024-04-30 Published:2025-07-23

摘要/Abstract

摘要： 目的探讨TRIB2在结肠癌中的表达水平及与预后及免疫浸润之间的关系。方法 TIMER数据库分析TRIB2在泛癌种中的表达;TCGA、GSE17538下载结肠癌患者RNA-seq数据和临床信息,评估其与临床病理特征的相关性;生存曲线、单因素和多因素Cox分析探讨TRIB2与预后的相关性,并构建列线图;对TRIB2进行差异基因的富集分析;分析TRIB2表达水平与免疫细胞浸润、免疫检查点、肿瘤突变负荷（TMB）以及免疫治疗敏感性之间的相关性。结果 TRIB2在结肠癌组织中高表达（P<0.05）;CMS1结肠癌患者TRIB2 mRNA表达水平最高;TRIB2是结肠癌患者的独立预后因素（单因素Cox回归分析：HR=1.397,95%CI：1.100~1.774,P=0.006;多因素Cox回归分析：HR=1.502,95%CI：1.158~1.947,P=0.002）;TRIB2与免疫细胞的浸润密切相关,并且与免疫检查点分子表达水平以及TMB正相关（r=0.39,P<0.001）;TRIB2的表达水平与免疫检查点抑制剂的疗效相关。结论 TRIB2在结肠癌中高表达且与结肠癌患者预后差和免疫微环境密切相关。

关键词: 结肠癌, TRIB2, 预后, 免疫

Abstract: Objective To explore the expression of TRIB2 in colon cancer and its relationship with prognosis and immune cell infiltration. Methods TIMER database was used to analyse the expression of TRIB2 in pan-cancer．RNA-seq data and clinical information of colon cancer patients were downloaded from TCGA and GSE17538 to assess the correlation between TRIB2 with clinicopathological features．Survival curves,univariate and multivariate COX regression analysis were performed to explore the correlation between TRIB2 and prognosis,and a nomogram was constructed．Gene enrichment analyses were performed for TRIB2．Correlations between TRIB2 expression and immune cell infiltration,immune checkpoints,tumor mutation burden（TMB）,and immunotherapy sensitivity were analyzed．Results TRIB2 was highly expressed in colon cancer tissues（P<0.05）．The highest level of TRIB2 mRNA expression was found in CMS1．TRIB2 was an independent prognostic factor for colon cancer patients（univariate Cox regression analysis：HR=1.397,95%CI：1.100-1.774,P=0.006;multivariate Cox regression analysis：HR=1.502,95%CI：1.158-1.947,P=0.002）．TRIB2 was closely associated with immune cell infiltration and positively correlated with the expression level of immune checkpoint molecules as well as TMB（r=0.39,P<0.001）．The expression of TRIB2 was correlated with the efficacy of immune checkpoint inhibitors．Conclusions TRIB2 is highly expressed in colon cancer and is closely associated with poor prognosis and the immune microenvironment of colon cancer patients．

Key words: colon cancer, TRIB2, prognosis, immunity

万璐颖, 李静宜, 谢贤和. 基于生物信息学分析TRIB2与结肠癌预后和免疫浸润相关性[J]. 广州医药, 2025, 56(6): 766-774.

WAN Luying, LI Jingyi, XIE Xianhe. Correlation of TRIB2 expression with prognosis and immune infiltration in colon cancer based on bioinformatics[J]. Guangzhou Medical Journal, 2025, 56(6): 766-774.

参考文献

[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34.
[2] 黄庆,索彩霞,何凤,等.结直肠癌的早期诊断策略和治疗进展[J].广州医药,2024.55(1):1-8.
[3] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
[4] BREAKSTONE R.Colon cancer and immunotherapy-can we go beyond microsatellite instability?[J].Transl Gastroenterol Hepatol,2021(6):12.
[5] NTAVATZIKOS A,SPATHIS A,PATAPIS P,et al.TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer[J].World J Gastrointest Oncol,2019,11(7):551-566.
[6] PETERSON C,DENLINGER N,YANG Y.Recent advances and challenges in cancer immunotherapy[J].Cancers(Basel),2022,14(16):3972.
[7] OLIVEIRA A F,BRETES L,FURTADO I.Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer[J].Front Oncol,2019(9):396.
[8] LIU I D,WILLIS N S,CRAIG J C,et al.Interventions for idiopathic steroid-resistant nephrotic syndrome in children[J].Cochrane Database Syst Rev,2019,2019(11):CD003594.
[9] LIU Y R,SONG D D,LIANG D M,et al.Oncogenic TRIB2 interacts with and regulates PKM2 to promote aerobic glycolysis and lung cancer cell procession[J].Cell Death Discov,2022,8(1):306.
[10] ROME K S,STEIN S J,KURACHI M,et al.Trib1 regulates T cell differentiation during chronic infection by restraining the effector program[J].J Exp Med,2020,217(5):e20190888.
[11] MAYORAL-VARO V,JIMÉNEZ L,LINK W,The critical role of TRIB2 in cancer and therapy resistance[J].Cancers(Basel),2021,13(11):2701.
[12] GUO S,CHEN Y,XUE X,et al.TRIB2 desensitizes ferroptosis via βTrCP-mediated TFRC ubiquitiantion in liver cancer cells[J].Cell Death Discov,2021,7(1):196.
[13] MAI Z,GUO K,SUN X,et al.Expression and related mechanisms of miR-100 and TRIB2 in COPD patients[J].J Healthc Eng,2022(2022):6556208.
[14] HOU Z,GUO K,SUN X,et al.TRIB2 functions as novel oncogene in colorectal cancer by blocking cellular senescence through AP4/p21 signaling[J].Mol Cancer,2018,17(1):172.
[15] YOSHIHARA K,SHAHMORADGOLI M,MARTÍNEZ E,et al.Inferring tumour purity and stromal and immune cell admixture from expression data[J].Nat Commun,2013(4):2612.
[16] NEWMAN A M,LIU C L,GREEN M R,et al.Robust enumeration of cell subsets from tissue expression profiles[J].Nat Methods,2015,12(5):453-457.
[17] WANG H,GAO Y,VAFAEI S,et al.A chemoresistance lncRNA signature for recurrence risk stratification of colon cancer patients with chemotherapy[J].Mol Ther Nucleic Acids,2022(27):427-438.
[18] LU H,SHI T,WANG M,et al.B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells[J].Oncoimmunology,2020,9(1):1748991.
[19] LIANG K,O’CONNOR C,VEIGA J P,et al.TRIB2 regulates normal and stress-induced thymocyte proliferation[J].Cell Discov,2016(2):15050.
[20] LI K,WANG F,YANG Z N,et al.TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation[J].Nat Commun,2020,11(1):6316.
[21] GUINNEY J,DIENSTMANN R,WANG X,et al.The consensus molecular subtypes of colorectal cancer[J].Nat Med,2015,21(11):1350-1356.
[22] LENZ H J,OU F S,VENOOK A P,et al.Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer:Results from CALGB/SWOG 80405(alliance)[J].J Clin Oncol,2019,37(22):1876-1885.
[23] SHOLL L M,HIRSCH F R,HWANG D,et al.The promises and challenges of tumor mutation burden as an immunotherapy biomarker:A perspective from the international association for the study of lung cancer pathology committee[J].J Thorac Oncol,2020,15(9):1409-1424.
[24] GROSSER R,CHERKASSKY L,CHINTALA N,et al.Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors[J].Cancer Cell,2019,36(5):471-482.

基于生物信息学分析TRIB2与结肠癌预后和免疫浸润相关性

Correlation of TRIB2 expression with prognosis and immune infiltration in colon cancer based on bioinformatics

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	武变荣, 骆玉霜. 免疫联合化疗对晚期NSCLC患者淋巴细胞免疫及生活质量的影响[J]. 广州医药, 2025, 56(6): 760-765.
[2]	谢红妹, 杨波, 徐维, 蔡利, 徐培培. 贝伐珠单抗联合化疗对晚期结直肠癌患者MSH2、MLHI、MSH6和PMS2水平影响[J]. 广州医药, 2025, 56(6): 809-814.
[3]	钟煜民, 黄冬连, 谢祖刚, 郭耿耿. 单克隆免疫球蛋白血症患者M蛋白质量浓度检测的临床意义[J]. 广州医药, 2025, 56(5): 669-674.
[4]	沈俊杰, 蔡勇, 钟兴明. CD28和PD-1在自发性脑出血预后中的研究进展[J]. 广州医药, 2025, 56(4): 446-451.
[5]	殷雨来, 何晓阳, 夏琳, 张晓宇. 三阴性乳腺癌Cox回归临床预测模型的构建与验证：基于SEER数据库[J]. 广州医药, 2025, 56(4): 457-468.
[6]	刘文政, 金明杰, 张宁, 刘金强, 常乐. 清醒镇静在急性缺血性脑卒中血管内治疗中的应用效果及预后[J]. 广州医药, 2025, 56(3): 382-386.
[7]	姚远, 尹亭亭. MDSCs在肿瘤免疫治疗中的研究进展[J]. 广州医药, 2025, 56(2): 151-159.
[8]	彭旭, 焦璐, 韩莹, 杨静, 赵信喜. ZEB1、LAMP5在结直肠癌组织中的表达水平分析及预后预测价值分析[J]. 广州医药, 2025, 56(2): 228-234.
[9]	黎霏霏, 宋丹丹, 潘春荣. 老年慢性心力衰竭患者血清SCD-1和sVEGFR-2表达水平及其与预后的评估价值研究[J]. 广州医药, 2025, 56(2): 241-246.
[10]	朱怡怡, 杨婵, 王振兴. 全身免疫炎症指数与心血管疾病相关研究进展[J]. 广州医药, 2024, 55(9): 985-990.
[11]	蒋馨悦, 徐婷. 血流感染患者血小板参数动态变化及其预后价值[J]. 广州医药, 2024, 55(9): 1066-1071.
[12]	李荣传, 陈海默, 庄金红. 丙戊酸钠联合奥卡西平治疗癫痫对患者炎性因子及疗效的影响[J]. 广州医药, 2024, 55(8): 923-928.
[13]	杨六红, 陈翔. 常见炎性指标与进展性脑梗死病灶损害程度的关联及对预后的预测效能分析[J]. 广州医药, 2024, 55(7): 764-769.
[14]	徐凝, 王丽娜, 刘国成, 刘雨丰. MDSCs调控新生儿免疫应答机制及其临床意义[J]. 广州医药, 2024, 55(5): 457-462.
[15]	张芬, 徐翼, 陈敏霞, 何登敏. IgG、IgA、IgM与hs-CRP联合对幼儿手足口病的病情诊断价值[J]. 广州医药, 2024, 55(4): 388-391.